Arrowhead Creates Hepatitis B Clinical Advisory Board and Names Dr. Robert Gish Chairman

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, announced today that prominent hepatologist Robert G. Gish, MD, will serve as Chairman of the company’s newly created hepatitis B Clinical Advisory Board. In this leadership role, Dr. Gish will assist with recruitment of additional advisory board members and will advise the company on clinical and regulatory approval strategy in addition to analysis, and interpretation of clinical trial results for the HBV program and its associated lead candidate, ARC-520.